Company intelligence / Profile preview

HUABIO

Woburn, Massachusetts, United States

Ownership: Private
Employees: ~89
Development stage: Other

Overview

HUABIO markets a catalogue of >11,000 antibodies supported by extensive validation, widely published in leading journals such as Nature and Science, with a focus on highly accurate, reproducible, and cruelty-free antibody production[3].

Therapeutic areas: Other
Modalities: AntibodyMonoclonal antibodyPolyclonal antibodyNanobodyRecombinant protein
Industry: Non-Drug Biotech

Partnerships

Partners with research organizations and pharma/biotech for antibody supply; specific major partnerships not disclosed publicly

Beyond the preview

Go deeper on HUABIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUABIO.

Explore the full profile